Example: Heart Attack

Search clinical trials for: Pioglitazone

Total 479 results

NCT04473274

Recruiting

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

Conditions: Coronavirus Infection; Diabetes
NCT04470310

Active, not recruiting

Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination

Conditions: Type 2 Diabetes Mellitus
NCT04419337

Recruiting

Antidiabetic Triple Therapy Effects on Surrogate Tests After Stroke

Conditions: Diabetes Mellitus; Stroke
NCT04392557

Not yet recruiting

Anti-inflammatory Status in DM2 Treated Patients

Conditions: Diabetes Mellitus, Type 2
NCT04370093

Active, not recruiting

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

Conditions: Nephrolithiasis, Uric Acid
NCT04300127

Recruiting

Pioglitazone for Idiopathic Gastroparesis

Conditions: Gastroparesis
NCT04287387

Not yet recruiting

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Conditions: Type2 Diabetes Mellitus
NCT04271189

Not yet recruiting

Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs

Conditions: Newly Diagnosed Type 2 Diabetes
NCT04227093

Recruiting

Acetazolamide Add-On Therapy to OSA Surgery

Conditions: Obstructive Sleep Apnea
NCT04123067

Recruiting

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

Conditions: Stroke, Acute; Hyperglycemia; Diabetes
NCT04113889

Completed

Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome

Conditions: PCOS
NCT04027023

Recruiting

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

Conditions: Diabetes Mellitus, Type 2
NCT04013581

Not yet recruiting

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Conditions: Type 2 Diabetes Mellitus
NCT03950505

Not yet recruiting

To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes

Conditions: Non-alcoholic Steatohepatitis; Type2 Diabetes
NCT03910361

Enrolling by invitation

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Conditions: Type2 Diabetes; Non-Alcoholic Fatty Liver Disease
NCT03878459

Suspended

Dapagliflozin Plus Pioglitazone in T1DM

Conditions: Type 1 Diabetes Mellitus
NCT03866408

Recruiting

Insulin Regulation of Lipolysis and Lipolysis Proteins

Conditions: Obesity
NCT03864146

Recruiting

Pioglitazone for the Treatment of Alcohol Use Disorder

Conditions: Alcohol Use Disorder
NCT03864523

Completed

Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy

Conditions: Adrenomyeloneuropathy; X-linked Adrenoleukodystrophy
NCT03860753

Recruiting

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving

Conditions: Alcohol Use Disorder
NCT03796975

Active, not recruiting

Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

Conditions: Type2 Diabetes Mellitus; Non-alcoholic Fatty Liver Disease
NCT03794518

Not yet recruiting

Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF

Conditions: Risk Reduction
NCT03757923

Recruiting

Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism

Conditions: Menstrual Irregularities; Hyperandrogenism
NCT03720366

Recruiting

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Conditions: Leukemia, Myeloid, Acute
NCT03646292

Not yet recruiting

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Conditions: NAFLD - Nonalcoholic Fatty Liver Disease; Type2 Diabetes
NCT03566225

Active, not recruiting

Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome

Conditions: Pioglitazone
NCT03501277

Completed

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Conditions: Healthy Volunteers
NCT03499704

Recruiting

A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

Conditions: Diabetes Mellitus, Type 2
NCT03492580

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases
NCT03471117

Unknown status

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Conditions: Chronic Kidney Diseases
NCT03457597

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Conditions: Healthy
NCT03452267

Not yet recruiting

Insulin Signaling in Skeletal Muscle

Conditions: Insulin Sensitivity
NCT03440034

Active, not recruiting

Study of Pioglitazone in Sporadic Inclusion Body Myositis

Conditions: Myositis; Inclusion Body Myositis; Muscular Diseases; Musculoskeletal Disease; Neuromuscular Diseases; Nervous System Diseases
NCT03335956

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Conditions: Healthy
NCT03298464

Completed

Study of NGM313 in Obese Participants

Conditions: Obese
NCT03231033

Completed

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
NCT03196362

Unknown status

Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes

Conditions: Type 2 Diabetes Mellitus
NCT03125694

Completed

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Conditions: Uncontrolled Type 2 Diabetes Mellitus
NCT03117517

Completed

Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome

Conditions: Polycystic Ovarian Syndrome
NCT03109288

Recruiting

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Conditions: Multiple Sclerosis
NCT03080480

Terminated

Pioglitazone Therapy for Chronic Granulomatous Disease

Conditions: Chronic Granulomatous Disease
NCT03060772

Recruiting

A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)

Conditions: Alcoholism
NCT03030300

Completed

Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy

Conditions: Type2 Diabetes
NCT03011775

Completed

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

Conditions: Adverse Effect; Atherosclerosis, Coronary; Insulin Resistance Syndrome
NCT02989649

Terminated

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Conditions: Diabetes Mellitus, Type 2
NCT02969798

Recruiting

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Conditions: Diabetes Mellitus, Type 2; Impaired Glucose Tolerance (IGT); Impaired Fasting Glucose (IFG)
NCT02958956

Completed

Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

Conditions: Diabetes Mellitus, Type 2, Cancer
NCT02942758

Recruiting

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

Conditions: Acute Myeloid Leukemia
NCT02919176

Completed

Brown Fat Activation Study

Conditions: Obese; Metabolic Syndrome
NCT02917629

Terminated

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Conditions: Oral Cavity Neoplasm; Oropharyngeal Neoplasm; Stage 0 Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7

Search clinical trials for: Pioglitazone

Recent CRA jobs

Safety Admin

Research Scientist - LCMS - Method Development

Data Analyst II – Real World Evidence

Clinical Team Manager (Local Study Manager) FSP

Senior Logistics Coordinator / Senior Sample Coordinator - Sample Management , LIMS , GMP

Associate HR Director - Business Partner

Associate Scientist - Part-time Weekends

QC Reviewer / Senior QC Reviewer - LIMS , GMP

Site Alliance Manager

Principal Clinical Database Programmer